Positivity of scaled up lung cancer leads compared with the <i>Early</i>CDT-Lung panel.

Cut-offs were optimized to give the maximum number of positive cancers and negative control samples for both the leads and the eCDT-Lung R&D panel antigens. Overall positivity in cancers and controls is given for each lead as well as the additive positivity over the eCDT-Lung R&D panel. Antigens defined as confirmed leads and taken forward for validation on a separate sample cohort are shown in bold italic font.